{
    "nctId": "NCT06301438",
    "briefTitle": "Dalpiciclib in HR+/HER2- ABC",
    "officialTitle": "Efficacy and Safety of Dalpiciclib in HR+/HER2- Advanced Breast Cancer: a Real-world Study",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Advanced Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 103,
    "primaryOutcomeMeasure": "Progression-Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed advanced breast cancer\n* Hormone receptor-positive and human epidermal growth factor receptor 2-negative\n* ECOG 0-1\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* History of immunodeficiency",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}